Injicerable Lenacapavir-Len, short-is a very effective, long-acting antiretroviral alternative to daily oral pills and other short-acting possibilities, according to the World Health Organization (WHO).
“While an HIV vaccine remains evasive, Lenacapavir is the next best thing: a long-acting antiretroviral shown in attempts to prevent almost all HIV infections among those in danger,” said Tedros Adhanom Ghebreyesus, as Director General.
Test -kit advantage
Who is support for the injectable drug is significant because HIV prevention efforts are stagnating around the world.
To make it easier for people to receive the injection close to the home, the UN Agency also recommends the use of quick test set for the diseaseUnlike “complex, expensive procedures”.
According to the Agency, 1.3 million people contracted in 2024; People who were most affected were sex workers, men who have sex with men, transient people, people injecting drugs, people into prisons and children and teens.
“Who is obliged to cooperate with countries and partners to ensure that this innovation reaches the communities as quickly and safely as possible,” Tedros insisted in comments during the 13th International AIDS Society Conference (IAS 2025) on HIV Science, in Kigali, Rwanda.
The recommendation for Len is also in line with the US health authorities who approved it in June.
Call for implementation
Although access to the LEN injection remains limited outside clinical trials today, which called on governments, donors and partners to incorporate the “immediately” within national combination of HIV prevention programs.
Other WHO-supported HIV prevention options include daily oral tablets, injectable cabotegravir — as is injected once every two months and dapivirin-gevinal ring, as part of a growing number of tools to end the HIV epidemic.
Financing of dilemma
In the midst of massive financing cuts to global efforts to end HIV -AAIDs – including the leading US government program launched in 2003, PepFar, focusing on the fight against the disease in Africa – which also issued new operating guidance on how to maintain prioritized HIV services.
“We have tools and knowledge to end AIDS … what we need now is bold implementation of these recommendations, grounded in equity and driven by society,” Said Dr. Meg Doherty, Director of WHO’s Institute for Global HIV, Hepatitis and Sti Programs and Incoming Director of Science, Research, Proof and Quality for Health.
HIV is still a big global public health issue.
By the end of 2024, an estimated 40.8 million people lived with HIV with an estimated 65 percent in Africa. About 630,000 people died for HIV-related reasons globally, and estimated 1.3 million people acquired HIV, including 120,000 children.
More positively, access to HIV drugs is expanded by expanding with 31.6 million people receiving treatment in 2024, up from 30.3 million a year earlier. Without anti-retroviral medication, the HIV virus indicates the body’s immune system, which eventually leads to the beginning of AIDS.
